Latest Breaking News On - Cizzle biotechnology ltd - Page 2 : comparemela.com
Ariana News Headlines AAU Share News Financial News Articles for Ariana Resources Plc Ord 0 1P updated throughout the day
lse.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lse.co.uk Daily Mail and Mail on Sunday newspapers.
IN BRIEF: Cizzle Biotechnology partners with St George Street Capital
lse.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lse.co.uk Daily Mail and Mail on Sunday newspapers.
Hardman & Co Research: Cizzle Biotechnology/Bould (CIZ): Early detection of lung cancer
DJ Hardman & Co Research: Cizzle Biotechnology/Bould (CIZ): Early detection of lung cancer
Hardman & Co Research
Hardman & Co Research: Cizzle Biotechnology/Bould (CIZ): Early detection of lung cancer
14-May-2021 / 10:50 GMT/BST
=
Hardman & Co Research: (Initiation of coverage) Early detection of lung cancer
Cizzle Biotechnology Ltd (Cizzle) was identified by Bould Opportunities (Bould) as its preferred target for a reverse
takeover. Cizzle is a spin-out from the University of York to exploit the biomarker, variant CIZ1b, for early detection
of different forms of lung cancer. The presence of nodules often detected on chest scans is suspicious, but not usually
IN BRIEF: Bould Opportunities sets sights on Cizzle Biotechnology
Fri, 23rd Apr 2021 16:16
Bould Opportunities PLC - cash shell - Agrees to buy Cizzle Biotechnology Ltd for GBP21 million, and intends for shares to be admitted to the Standard Listing segment of the Official List and trading on the Main Market of the London Stock Exchange, all of which are subject to shareholder approval at a general meeting.
Bould, formerly known as Photonstart LED Group, was classified as a cash shell on April 5. Cizzle Biotechnology is a spin-out from the University of York, founded in 2006, and is focused on patent protected technology for the early detection of lung cancer through the development of a blood test for the CIZ1B biomarker.